Related Experiment Video

Updated: Jul 6, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis

Carmen M Stanca1, Nancy Bach, Jorge Allina

  • 1Department of Medicine, The Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1633, New York, NY 10029, USA. cstanca@lmcmc.com

Digestive Diseases and Sciences
|April 9, 2008
PubMed

Insights

Long-term atorvastatin treatment effectively reduced LDL-cholesterol in primary biliary cirrhosis patients. However, this study found no evidence of anti-inflammatory effects from statin use in this condition.

Area of Science:

  • Hepatology
  • Pharmacology

Background:

  • Statins are known to reduce hypercholesterolemia and may possess anti-inflammatory properties.
  • Previous case reports suggested potential benefits of statin treatment in primary biliary cirrhosis, including reduced alkaline phosphatase and improved histology.

Purpose of the Study:

  • To evaluate the long-term efficacy of statin therapy in managing primary biliary cirrhosis.
  • To assess the impact of atorvastatin on lipid profiles and inflammatory markers in patients with primary biliary cirrhosis.

Main Methods:

  • A retrospective analysis was conducted comparing 15 hypercholesterolemic primary biliary cirrhosis patients treated with atorvastatin to an age and gender-matched control group.
  • Clinical and biochemical data, including cholesterol levels, liver enzymes, bilirubin, and Mayo Risk Score, were analyzed over a median treatment period of 2.5 years.

Main Results:

  • Atorvastatin treatment led to a significant reduction in total cholesterol and low-density lipoprotein (LDL)-cholesterol (p <= 0.002).
  • No significant changes in LDL-cholesterol were observed in the control group after 2 years (p > 0.050).
  • No significant alterations in alanine aminotransferase (ALT), alkaline phosphatase, total bilirubin, or Mayo Risk Score were detected in either the treatment or control groups.

Conclusions:

  • Long-term atorvastatin therapy effectively lowers LDL-cholesterol in patients with primary biliary cirrhosis.
  • The study found no evidence to support an anti-inflammatory effect of atorvastatin in this patient population.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...